• About MicuRx

    About MicuRx

    • 2022
      Contezolid tablet (MRX-I tablet) is added to the most recent National Reimbursement Drug List (NRDL) in China.
    • 2021
      China National Medical Products Administration (NMPA) approves Contezolid tablet (MRX-I tablet), for treatment of Complicated Skin and Soft Structure Infection
    • 2020
      NDA of MRX-I tablets accepted and priority review granted by the National Medical Products Administration (NMPA)
      MRX-8 IND approved in the US
      Series D and E Financing
    • 2019
      MRX-I Phase 3 clinical trial completed and New Drug Application (NDA) submitted in China
      MRX-4 Phase 2 clinical trial in the US
    • 2018
      Qualified Infectious Disease Product (QIDP) and Fast Track granted for MRX-I and MRX-4 in the US
      MRX-4 IND approved in China
    • 2017
      MRX-4 Phase 1 clinical trial in the US
    • 2016
      MRX-I Phase 2 clinical trial completed in the US
      Series C financing
    • 2015
      MRX-I Phase 2 clinical trial completed in China
      Patents for MRX-4 and MRX-8 filed
    • 2014
      MRX-I Phase 1 clinical trial in Australia
    • 2013
      Series B financing
      MRX-I supplementary application approved in China
    • 2012
      MRX-I supplementary application submitted in China
    • 2011
      MRX-I Phase 1 clinical trial in China
    • 2010
      MRX-I IND approved in China
    • 2009
      MRX-I investigation new drug (IND) application submitted in China
    • 2008
      First drug candidate MRX-I discovered, patent filed
    • 2007
      MicuRx founded in Shanghai and California
      Series A financing